A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma

Cancer Cell

Volumn 24, Issue 4, 2013, Pages 466-480

  Caramel, Julie ^a,b,c,d,e   Papadogeorgakis, Eftychios ^f   Hill, Louise ^a,b,c,d,e,f   Browne, GarethJ ^f   Richard, Geoffrey ^a,b,c,d,e   Wierinckx, Anne ^a,b,c,d,e,g   Saldanha, Gerald ^f   sborne, Joy ^h   Hutchinson, Peter ^f   Tse, Gina ^f   Lachuer, Joël ^a,b,c,d,e,g   Puisieux, Alain ^a,b,c,d,e,i   Pringle, J Howard ^f   Ansieau, Stéphane ^a,b,c,d,e   Tulchinsky, Eugene ^f  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b LabEx DEVweCAN   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITÉ DE LYON   (France)

^e CENTRE LÉON BÉRARD   (France)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g ProfileXpert   (France)

^h UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

ⁱ INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; RAS PROTEIN; SNAIL2 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB1; TUMOR SUPPRESSOR PROTEIN; TWIST1 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; ZEB2 PROTEIN;

ANIMAL CELL; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL INVASION; CONTROLLED STUDY; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE SWITCHING; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL;

EID: 84885377160     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.08.018     Document Type: Article

References (66)

1. Alexaki V.I., Javelaud D., Van Kempen L.C., Mohammad K.S., Dennler S., Luciani F., Hoek K.S., Juàrez P., Goydos J.S., Fournier P.J., et al. GLI2-mediated melanoma invasion and metastasis. J.Natl. Cancer Inst. 2010, 102:1148-1159.
2. Andersen K., Nesland J.M., Holm R., Flørenes V.A., Fodstad O., Maelandsmo G.M. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod. Pathol. 2004, 17:990-997.
3. Ansieau S., Bastid J., Doreau A., Morel A.P., Bouchet B.P., Thomas C., Fauvet F., Puisieux I., Doglioni C., Piccinin S., et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008, 14:79-89.
4. Bell R.E., Levy C. The three M's: melanoma, microphthalmia-associated transcription factor and microRNA. Pigment Cell Melanoma Res. 2011, 24:1088-1106.
5. Bertolotto C., Lesueur F., Giuliano S., Strub T., de Lichy M., Bille K., Dessen P., d'Hayer B., Mohamdi H., Remenieras A., et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011, 480:94-98. French Familial Melanoma Study Group.
6. Brabletz T. EMT and MET in metastasis: where are the cancer stem cells?. Cancer Cell 2012, 22:699-701.
7. Brabletz T. To differentiate or not-routes towards metastasis. Nat. Rev. Cancer 2012, 12:425-436.
8. Brabletz S., Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer?. EMBO Rep. 2010, 11:670-677.
9. Casalino L., De Cesare D., Verde P. Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol. Cell. Biol. 2003, 23:4401-4415.
10. Casas E., Kim J., Bendesky A., Ohno-Machado L., Wolfe C.J., Yang J. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 2011, 71:245-254.
11. Cheli Y., Ohanna M., Ballotti R., Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 2010, 23:27-40.
12. Cheli Y., Giuliano S., Botton T., Rocchi S., Hofman V., Hofman P., Bahadoran P., Bertolotto C., Ballotti R. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 2011, 30:2307-2318.
13. Chng Z., Teo A., Pedersen R.A., Vallier L. SIP1 mediates cell-fate decisions between neuroectoderm and mesendoderm in human pluripotent stem cells. Cell Stem Cell 2010, 6:59-70.
14. Dave N., Guaita-Esteruelas S., Gutarra S., Frias A., Beltran M., Peiró S., de Herreros A.G. Functional cooperation between Snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition. J.Biol. Chem. 2011, 286:12024-12032.
15. Emery C.M., Vijayendran K.G., Zipser M.C., Sawyer A.M., Niu L., Kim J.J., Hatton C., Chopra R., Oberholzer P.A., Karpova M.B., et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. USA 2009, 106:20411-20416.
16. Gupta P.B., Kuperwasser C., Brunet J.P., Ramaswamy S., Kuo W.L., Gray J.W., Naber S.P., Weinberg R.A. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat. Genet. 2005, 37:1047-1054.
17. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
18. Hill L., Browne G., Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int. J. Cancer 2013, 132:745-754.
19. Hodis E., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., Nickerson E., Auclair D., Li L., Place C., et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
20. Hoek K.S., Goding C.R. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 2010, 23:746-759.
21. Hoek K., Rimm D.L., Williams K.R., Zhao H., Ariyan S., Lin A., Kluger H.M., Berger A.J., Cheng E., Trombetta E.S., et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 2004, 64:5270-5282.
22. Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 2006, 19:290-302.
23. Hugo H.J., Kokkinos M.I., Blick T., Ackland M.L., Thompson E.W., Newgreen D.F. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study. Cells Tissues Organs (Print) 2011, 193:23-40.
24. Hüsemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., Forni G., Eils R., Fehm T., Riethmüller G., Klein C.A. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
25. Iliopoulos D., Hirsch H.A., Wang G., Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 2011, 108:1397-1402.
26. Karreth F.A., Tay Y., Perna D., Ala U., Tan S.M., Rust A.G., DeNicola G., Webster K.A., Weiss D., Perez-Mancera P.A., et al. Invivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 2011, 147:382-395.
27. Korpal M., Ell B.J., Buffa F.M., Ibrahim T., Blanco M.A., Celià-Terrassa T., Mercatali L., Khan Z., Goodarzi H., Hua Y., et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 2011, 17:1101-1108.
28. Li W., Song L., Ritchie A.M., Melton D.W. Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype. Pigment Cell Melanoma Res. 2012, 25:188-199.
29. Liu Y., Ye F., Li Q., Tamiya S., Darling D.S., Kaplan H.J., Dean D.C. Zeb1 represses Mitf and regulates pigment synthesis, cell proliferation, and epithelial morphology. Invest. Ophthalmol. Vis. Sci. 2009, 50:5080-5088.
30. Maestro R., Dei Tos A.P., Hamamori Y., Krasnokutsky S., Sartorelli V., Kedes L., Doglioni C., Beach D.H., Hannon G.J. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999, 13:2207-2217.
31. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
32. Martin M.J., Hayward R., Viros A., Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012, 2:344-355.
33. Mejlvang J., Kriajevska M., Vandewalle C., Chernova T., Sayan A.E., Berx G., Mellon J.K., Tulchinsky E. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol. Biol. Cell 2007, 18:4615-4624.
34. Mikesh L.M., Kumar M., Erdag G., Hogan K.T., Molhoek K.R., Mayo M.W., Slingluff C.L. Evaluation of molecular markers of mesenchymal phenotype in melanoma. Melanoma Res. 2010, 20:485-495.
35. Miller A.J., Mihm M.C. Melanoma. N.Engl. J. Med. 2006, 355:51-65.
36. Miyoshi T., Maruhashi M., Van De Putte T., Kondoh H., Huylebroeck D., Higashi Y. Complementary expression pattern of Zfhx1 genes Sip1 and deltaEF1 in the mouse embryo and their genetic interaction revealed by compound mutants. Dev. Dyn. 2006, 235:1941-1952.
37. Morel A.P., Lièvre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888.
38. Morel A.P., Hinkal G.W., Thomas C., Fauvet F., Courtois-Cox S., Wierinckx A., Devouassoux-Shisheboran M., Treilleux I., Tissier A., Gras B., et al. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet. 2012, 8:e1002723.
39. Nieto M.A., Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin. Cancer Biol. 2012, 22:361-368.
40. Nikolaev S.I., Rimoldi D., Iseli C., Valsesia A., Robyr D., Gehrig C., Harshman K., Guipponi M., Bukach O., Zoete V., et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 2012, 44:133-139.
41. Ocaña O.H., Córcoles R., Fabra A., Moreno-Bueno G., Acloque H., Vega S., Barrallo-Gimeno A., Cano A., Nieto M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22:709-724.
42. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 2007, 7:415-428.
43. Prickett T.D., Wei X., Cardenas-Navia I., Teer J.K., Lin J.C., Walia V., Gartner J., Jiang J., Cherukuri P.F., Molinolo A., et al. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat. Genet. 2011, 43:1119-1126.
44. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.
45. Saldanha G., Purnell D., Fletcher A., Potter L., Gillies A., Pringle J.H. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int. J. Cancer 2004, 111:705-710.
46. Sánchez-Martín M., Rodríguez-García A., Pérez-Losada J., Sagrera A., Read A.P., Sánchez-García I. SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum. Mol. Genet. 2002, 11:3231-3236.
47. Sanders D.S., Blessing K., Hassan G.A., Bruton R., Marsden J.R., Jankowski J. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. MP, Mol. Pathol. 1999, 52:151-157.
48. Scolyer R.A., Murali R., Satzger I., Thompson J.F. The detection and significance of melanoma micrometastases in sentinel nodes. Surg. Oncol. 2008, 17:165-174.
49. Shah M., Bhoumik A., Goel V., Dewing A., Breitwieser W., Kluger H., Krajewski S., Krajewska M., Dehart J., Lau E., et al. A role for ATF2 in regulating MITF and melanoma development. PLoS Genet. 2010, 6:e1001258.
50. Shin S., Dimitri C.A., Yoon S.O., Dowdle W., Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol. Cell 2010, 38:114-127.
51. Shirley S.H., Greene V.R., Duncan L.M., Torres Cabala C.A., Grimm E.A., Kusewitt D.F. Slug expression during melanoma progression. Am. J. Pathol. 2012, 180:2479-2489.
52. Stoecklein N.H., Hosch S.B., Bezler M., Stern F., Hartmann C.H., Vay C., Siegmund A., Scheunemann P., Schurr P., Knoefel W.T., et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008, 13:441-453.
53. Taube J.H., Herschkowitz J.I., Komurov K., Zhou A.Y., Gupta S., Yang J., Hartwell K., Onder T.T., Gupta P.B., Evans K.W., et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 2010, 107:15449-15454.
54. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
55. Tsai J.H., Donaher J.L., Murphy D.A., Chau S., Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012, 22:725-736.
56. Udart M., Utikal J., Krähn G.M., Peter R.U. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 2001, 3:245-254.
57. Uribe P., Andrade L., Gonzalez S. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J.Invest. Dermatol. 2006, 126:161-166.
58. Valsesia-Wittmann S., Magdeleine M., Dupasquier S., Garin E., Jallas A.C., Combaret V., Krause A., Leissner P., Puisieux A. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 2004, 6:625-630.
59. Van de Putte T., Francis A., Nelles L., van Grunsven L.A., Huylebroeck D. Neural crest-specific removal of Zfhx1b in mouse leads to a wide range of neurocristopathies reminiscent of Mowat-Wilson syndrome. Hum. Mol. Genet. 2007, 16:1423-1436.
60. Vega S., Morales A.V., Ocaña O.H., Valdés F., Fabregat I., Nieto M.A. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004, 18:1131-1143.
61. Venesio T., Chiorino G., Balsamo A., Zaccagna A., Petti C., Scatolini M., Pisacane A., Sarotto I., Picciotto F., Risio M. In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod. Pathol. 2008, 21:716-726.
62. Vial E., Sahai E., Marshall C.J. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003, 4:67-79.
63. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X., Gimotty P.A., Kee D., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695.
64. Wajapeyee N., Serra R.W., Zhu X., Mahalingam M., Green M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
65. Wellbrock C., Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J.Cell Biol. 2005, 170:703-708.
66. Yazdi A.S., Ghoreschi K., Sander C.A., Röcken M. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation. Eur. J. Dermatol. 2010, 20:575-579.